Sensorion Announces Initiation of Coverage by US Investment Bank Chardan with a “Buy” Recommendation

A pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the healthcare investment bank Chardan has initiated analyst coverage of Sensorion.

Chardan initiated coverage with a “Buy” rating and a price target of €2,00, based on its potential to become a leader in developing gene therapies to treat hearing loss.

Chardan joins Bryan Garnier & Co, whose analyst also initiated coverage on the company with a “Buy” rating in December 2019.

All reports on Sensorion prepared by analysts represent the views of those analysts and not necessarily those of Sensorion. Sensorion is not responsible for the content, accuracy, or timing of analyst reports. A copy of the full analyst note can be obtained directly from Chardan.

This information does not constitute an offer to sell or subscribe, or the solicitation of an order to buy or subscribe for securities in France, Europe, the US or any other country. – Bio Space